This raises the questions whether sometimes untreated disseminated EGFRM+ LACs may already contain a population of TKI-resistant SCLC cells as potential mechanism of inherent resistance and whether EGFR-TKI treatment can further select and expand this population giving rise to a genetically similar SCLC with acquired TKI-resistance [196]. This evidence concerns the gene EGFR and small cell lung carcinoma.